Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales

Published 4 days ago Negative
Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales
Auto

Related Stocks

NOVO-B.CO Novo Nordisk A/...
Novo Nordisk pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports.

View Comments

More News

George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Association’s Scientific Sessions 2025

59 minutes ago Negative

Can Apple Shares Surge Past $300 This Year?

1 hour ago Positive

Weekly Market Brief: Musk's trillion-dollar ambition, Expedia, GTA VI, and government shutdown

1 hour ago Positive

CYTK SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit

1 hour ago Negative

Why PureCycle Technologies (PCT) Is Down 9.0% After Record Resin Output and EU Grant Progress – And What’s Next

1 hour ago Positive